Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nephrol Ther ; 18(6): 565-569, 2022 Nov.
Artigo em Francês | MEDLINE | ID: mdl-35915034

RESUMO

INTRODUCTION: Lenalidomide is an immunomodulatory drug widely used in the treatment of multiple myeloma. Several cases of nephrotoxicity have been reported, but few have been documented histologically. CASE PRESENTATION: We report a case of acute interstitial nephritis to lenalidomide in a 62-year-old patient with multiple myeloma after administration of the second course of chemotherapy according to the protocol combining bortezomib, lenalidomide and dexamethasone. The outcome was quickly favorable after stopping lenalidomide, with corticosteroid therapy. CONCLUSION: Lenalidomide may be responsible for acute interstitial nephritis. When acute kidney injury occurs in myeloma, the nephrotoxicity of therapeutic agents should be considered in addition to the common causes of kidney failure. The chronology of events and the histological data are essential and guide the specific management.


Assuntos
Injúria Renal Aguda , Mieloma Múltiplo , Nefrite Intersticial , Humanos , Pessoa de Meia-Idade , Lenalidomida/efeitos adversos , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/complicações , Mieloma Múltiplo/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Nefrite Intersticial/induzido quimicamente , Nefrite Intersticial/complicações , Injúria Renal Aguda/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...